Biomarkers in Oncology Trials: What They Promise and What They Quietly Complicate

There’s a version of oncology drug development that looks very straightforward on paper. You identify a biomarker, enrich your population, conduct a tighter trial, and obtain a clearer signal. Everyone seems to benefit, and sometimes, that’s exactly what happens. However, if you’ve actually sat in the middle of an active study, watching patients enroll, reviewing data in real-time, fielding questions from sites, you know it’s not that straightforward. 

Biomarkers don’t just enhance trials, they reshape them. They introduce new dependencies, new blind spots, and new kinds of decisions that aren’t always obvious until the trial is underway.

This is where things get interesting, and where medical monitoring becomes less about checking boxes and more about interpreting reality as it unfolds.

The promise of biomarkers is real, but so is their fragility

Biomarkers have undeniably revolutionized oncology. We’ve moved from broad, histology-based approaches to something far more precise. For example, NPM1 in AML, EGFR in lung cancer, HER2 in breast, and PD-L1 across multiple tumors. These aren’t just labels, they’re entry points into the biology.

These biomarkers allow us to ask better questions and, in many cases, they help us find answers faster. But what often gets underestimated is how fragile that precision can be in practice. A biomarker isn’t just a biological truth; it’s also a test that operates in the real world. Different labs, different assays, different thresholds, and different turnaround times.

I’ve seen trials where eligibility depended on a biomarker result that arrived late, was borderline, or came from a local lab using a slightly different methodology than the central one. On paper, it’s straightforward: eligible or not. However, in reality, it often exists in a gray zone.

Once you start enrolling patients based on something that isn’t as straightforward as it looks, your trial population begins to drift, subtly, but significantly.

Enrichment comes with trade-offs

We frequently talk about enrichment strategies, specifically selecting patients more likely to respond based on biomarker status. And yes, that can dramatically improve response rates, making early-phase data look compelling and accelerating development. However, there’s a cost.

When you narrow your population, you also narrow your understanding. You lose context around how the drug behaves outside that biomarker-defined group. You limit your ability to detect unexpected toxicities that may not be biomarker-dependent and, sometimes, you overestimate how clean the biology really is. After all, biology doesn’t always conform to our categories.

I’ve seen patients who technically met biomarker criteria but didn’t behave the way the mechanism would suggest. Conversely, others who didn’t meet criteria, but clinically looked like they might benefit.

These moments force uncomfortable questions, not about the drug, necessarily, but about the assumptions we built the trial on.

Biomarkers don’t eliminate uncertainty; they relocate it

There’s a tendency to think biomarkers reduce ambiguity. In reality, they just move it. Instead of asking, “Does this drug work in this disease?” we start asking, “Does this biomarker truly define the disease subset we think it does?” or “Are we measuring the right thing, at the right time, using the right method?”

Take dynamic biomarkers, things that change over time. These include circulating tumor DNA (ctDNA), minimal residual disease (MRD), and immune signatures. Now, your readout isn’t just a baseline eligibility gate; it’s something that evolves, and this introduces a different kind of complexity.

If a patient’s biomarker status changes mid-treatment, what does that mean? Is it a sign of response, resistance, assay variability, or something else entirely? These aren’t theoretical questions; they show up in real patients, in real time, often without clear answers. And consequently someone has to make a call.

Where medical monitoring actually sits in this

This is the part that doesn’t get talked about enough. Biomarkers are often framed as a design feature, a protocol decision, or a statistical strategy. But once the trial starts, they become operational and clinical.

As a medical monitor, you’re not just looking at whether a patient met inclusion criteria. You’re asking whether that biomarker result makes sense in the clinical context. You’re looking at discordant cases, where the biomarker says one thing, and the clinical picture says another. You’re tracking patterns across sites. Are certain centers enrolling borderline patients more often? Are there delays in biomarker testing that are pushing enrollment decisions into uncomfortable territory? You’re also watching safety through a biomarker-informed lens. Because sometimes toxicity clusters in ways that correlate with biology, not just dose or exposure, and if you’re not paying attention to that layer, you miss the early signal.

This is where the role becomes less procedural and more interpretive. You’re connecting dots that weren’t explicitly linked in the protocol, asking questions that don’t have predefined answers, and you’re doing it while the study is still moving forward.

The silent risk: overconfidence

One of the more subtle risks with biomarker-driven trials is overconfidence. When you believe your biomarker is “the right one,” it’s easy to become less skeptical. You assume that unexpected outcomes are anomalies rather than signals.

I’ve seen this happen in early-phase studies where response rates looked strong in a biomarker-positive population. There was a tendency to attribute everything, good and bad, to the biomarker framework. But then you start seeing inconsistencies. Variability in response depth, unexpected adverse events, and patients who don’t fit the pattern. That’s when you realize the biomarker isn’t the full story, it’s just one piece.

The danger isn’t in using biomarkers, but in believing they’ve simplified something that is still inherently complex.

Where this is all heading

We’re moving toward increasingly sophisticated biomarker strategies. These strategies include multi-omic profiling, composite biomarkers, and adaptive trial designs that adjust based on biomarker signals in real-time. This progress is exciting and necessary, but it also means the burden on interpretation is only going to increase.

As we introduce more layers of data, we need more people who can make sense of them, not just statistically, but clinically. This is the gap I see emerging. It’s not in technology or in assay development, but in how we integrate these signals into real-time decision-making.

The part we shouldn’t overlook

At the end of all of this, behind every biomarker, every assay, every eligibility criterion, there’s still a patient. These patients either get access to a trial or don’t, based on how we define and apply these markers. And those decisions are rarely as straightforward as they look in the protocol. That’s why this work can’t be purely technical. It requires judgment, context, and a willingness to question assumptions, even the ones that feel well-established. 

Because biomarkers don’t remove the need for clinical thinking. If anything, they make it more essential.

Final thought 

Biomarkers have transformed oncology trials by making development smarter, faster, and more targeted. But they haven’t made it simpler. If you’re working in this space, the real skill isn’t just understanding the biomarker, it’s understanding where it breaks, where it blurs, and where it quietly shapes decisions in ways we don’t always acknowledge. This is where the real work lies, and that’s where the impact is made.

-The Medical Monitor’s Desk